Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Progesterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Progesterone SCHEMBL3931579 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL15493962 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL16305628 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL14546167 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL13752811 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL7900795 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL23568915 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL418975 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL9120521 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL6661427 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023174947-A1 | ESTETROL FOR USE IN RE-ENDOTHELIALIZATION | ESTETRA SRL (BE) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023288123-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF 3.ALPHA.,7.ALPHA.,11.BETA.-TRIHYDROXY-6.ALPHA.-ETHYL-5.BETA.-CHOLAN-24-OIC ACID | INTERECEPT PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2017173191-A1 | STEROID HORMONE COMPOSITIONS IN MEDIUM CHAIN OILS | THERAPEUTICSMD, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017173185-A1 | STEROID HORMONE PHARMACEUTICAL COMPOSITION | THERAPEUTICSMD, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-9572818-B2 | Pharmaceutical emulsion compositions comprising progestogen | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2017-02-21 | — | — | US | disclosed |
| US-9572818-B2 | Pharmaceutical emulsion compositions comprising progestogen | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2017-02-21 | — | — | US | disclosed |
| US-9504697-B2 | Progesterone treatment for improving sleep quality | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2016-11-29 | — | — | US | disclosed |
| US-9504697-B2 | Progesterone treatment for improving sleep quality | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2016-11-29 | — | — | US | disclosed |
| US-20150320767-A1 | PROGESTERONE TREATMENT FOR IMPROVING SLEEP QUALITY | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2015-11-12 | — | — | US | disclosed |
| US-20150320767-A1 | PROGESTERONE TREATMENT FOR IMPROVING SLEEP QUALITY | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2015-11-12 | — | — | US | disclosed |
| US-20140147474-A1 | PHARMACEUTICAL EMULSION COMPOSITIONS COMPRISING PROGESTOGEN | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2014-05-29 | — | — | US | disclosed |
| US-20140147474-A1 | PHARMACEUTICAL EMULSION COMPOSITIONS COMPRISING PROGESTOGEN | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2014-05-29 | — | — | US | disclosed |
| US-20140127185-A1 | METHODS AND COMPOSITIONS USING NEUROPROTECTIVE STEROIDS AND THROMBOLYTIC AGENTS | EMORY UNIVERSITY (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140127185-A1 | METHODS AND COMPOSITIONS USING NEUROPROTECTIVE STEROIDS AND THROMBOLYTIC AGENTS | EMORY UNIVERSITY (US) | 2014-05-08 | — | — | US | disclosed |
| WO-2014071005-A1 | METHODS AND COMPOSITIONS USING NEUROPROTECTIVE STEROIDS AND THROMBOLYTIC AGENTS | EMORY UNIVERSITY (US) | 2014-05-08 | — | — | WO | disclosed |
| US-8476252-B2 | Pharmaceutical emulsion compositions comprising progestogen | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2013-07-02 | — | — | US | disclosed |
| US-20120302535-A1 | PROGESTERONE TREATMENT FOR IMPROVING SLEEP QUALITY | BESINS HEALTHCARE LUXEMBOURG SARL | 2012-11-29 | — | — | US | disclosed |
| US-20110262494-A1 | LOW-OIL PHARMACEUTICAL EMULSION COMPOSITIONS COMPRISING PROGESTOGEN | BESINS HEALTHCARE LUXEMBOURG SARL | 2011-10-27 | — | — | US | disclosed |
| US-20110262495-A1 | PHARMACEUTICAL EMULSION COMPOSITIONS COMPRISING PROGESTOGEN | BESINS HEALTHCARE LUXEMBOURG SARL | 2011-10-27 | — | — | US | disclosed |
| US-7238507-B2 | Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase | PHARMACIA CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302535-A1 | PROGESTERONE TREATMENT FOR IMPROVING SLEEP QUALITY | MTNR1B, CYP27B1, PGR | PGR 3/4885CYP3A4 456/4885LMNA 1294/4885 |
| US-20140127185-A1 | METHODS AND COMPOSITIONS USING NEUROPROTECTIVE STEROIDS AND THROMBOLYTIC AGENTS | PLG, PLAT, SERPINE1 | PGR 89/4885CYP3A4 2401/4885LMNA 309/4885 |
| US-20110262495-A1 | PHARMACEUTICAL EMULSION COMPOSITIONS COMPRISING PROGESTOGEN | PGR, CYP17A1, CYP19A1 | PGR 1/4885CYP3A4 287/4885LMNA 2809/4885 |
| US-20150320767-A1 | PROGESTERONE TREATMENT FOR IMPROVING SLEEP QUALITY | MTNR1B, CYP27B1, PGR | PGR 3/4885CYP3A4 456/4885LMNA 1294/4885 |
| US-20140147474-A1 | PHARMACEUTICAL EMULSION COMPOSITIONS COMPRISING PROGESTOGEN | PGR, CYP17A1, CYP19A1 | PGR 1/4885CYP3A4 287/4885LMNA 2809/4885 |
| US-20110262494-A1 | LOW-OIL PHARMACEUTICAL EMULSION COMPOSITIONS COMPRISING PROGESTOGEN | PGR, CYP17A1, PGRMC1 | PGR 1/4885CYP3A4 696/4885LMNA 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.